CinCor Pharma ^{Priced, Nasdaq: CINC}

We are a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Despite the widespread availability of multiple antihypertensive agents, there remains a significant unmet medical need as more than half of the 108 million hypertensive patients in the US do not achieve blood pressure control. We are evaluating the efficacy and safety profile of CIN-107 as a potential treatment for the broader hypertensive population, including different subpopulations who have not achieved blood pressure control despite treatment, and are currently in two Phase 2 trials for different subpopulations. In addition to hypertension, we are developing CIN-107 for primary aldosteronism, or PA, and exploring its utility in ameliorating complications of chronic kidney disease, or CKD. Earlier this year, we initiated a Phase 2 trial of CIN-107 in patients with confirmed PA, and plan to initiate a Phase 2 trial in patients with CKD who have uncontrolled blood pressure in the first half of 2022.